Publications



Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era.
MBio 2017 Jul 25;8(4). Epub 2017 Jul 25.
Laboratory for Antimicrobial Dynamics, NYS Center of Excellence in Bioinformatics and Life Sciences, Buffalo, New York, USA


Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Pharmacogenet Genomics 2017 May;27(5):190-196
aDepartment of Pharmacotherapy and Translational Research bCenter for Pharmacogenomics, College of Pharmacy, University of Florida cUniversity of Florida Health Shands Hospital, Gainesville dDepartment of Pharmaceutics eCenter for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando fDepartment of Medicine, Division of Hematology and Oncology gDepartment of Medicine, Division of Cardiology, College of Medicine, University of Florida, Gainesville, Florida, USA.



Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.
Antimicrob Agents Chemother 2016 Nov 21;60(11):6591-6599. Epub 2016 Oct 21.
Tuberculosis Research Unit, Department of Medicine, Case Western Reserve University School of Medicine, and University Hospitals Case Medical Center, Cleveland, Ohio, USA.




Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.
Pediatr Infect Dis J 2016 Apr;35(4):414-21
From the *Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; †Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida; ‡Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; §Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina; ¶North Bay Pediatrics, Vallejo, California; ‖Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado; **TB/Leprosy Program, Federated States of Micronesia (FSM); ††Francis J. Curry International TB Center, San Francisco, California; and ‡‡Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida.

CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
Pharmacotherapy 2014 Jul 7;34(7):703-18. Epub 2014 Feb 7.
Icahn School of Medicine at Mount Sinai, The Charles Bronfman Institute for Personalized Medicine, New York, New York; Department of Pharmacy, The Mount Sinai Hospital, New York, New York.


Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.
Pharmacotherapy 2014 Mar 13;34(3):265-71. Epub 2014 Jan 13.
Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island; The Miriam Hospital, Providence, Rhode Island.

Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
Antimicrob Agents Chemother 2013 Aug 3;57(8):3910-6. Epub 2013 Jun 3.
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.
J Antimicrob Chemother 2012 Sep 8;67(9):2182-90. Epub 2012 Jun 8.
Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.

Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
Antimicrob Agents Chemother 2012 Aug 4;56(8):4331-40. Epub 2012 Jun 4.
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus.
Antimicrob Agents Chemother 2012 Jul 23;56(7):3712-9. Epub 2012 Apr 23.
Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA.

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Antimicrob Agents Chemother 2012 Jun 2;56(6):3114-20. Epub 2012 Apr 2.
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.
Antimicrob Agents Chemother 2011 Mar 6;55(3):1237-47. Epub 2010 Dec 6.
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA.

Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis.
Am J Trop Med Hyg 2009 Aug;81(2):322-9
Clinical Research Unit and Institute of Biomedicine/Center for Global Health, Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis.
Braz J Infect Dis 2009 Jun;13(3):210-7
Clinical Research Unit & Institute of Biomedicine, Center for Global Health, Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceará, Fortaleza.

Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis.
Am J Respir Crit Care Med 2008 Dec 11;178(11):1180-5. Epub 2008 Sep 11.
Núcleo de Doenças Infecciosas Centro de Ciências da Saúde, Universidade Federal do Espírito Santo, Av. Marechal Campos, 1468 Maruípe,Vitória-ES Brazil, CEP 29040-091.

Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
Bioorg Med Chem Lett 2008 May 18;18(10):3029-33. Epub 2008 Apr 18.
Institute of Chemical Biology and Drug Discovery, Department of Chemistry, Stony Brook University, Stony Brook, NY 11794-3400, USA.


Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis.
Braz J Infect Dis 2006 Dec;10(6):374-9
Clinical Research Unit & Institute of Biomedicine/Center for Global Health, Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil.

Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.
Antimicrob Agents Chemother 2015 16;59(6):3149-55. Epub 2015 Mar 16.
Division of Infectious Diseases Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA Departments of Epidemiology and Global Health, Emory Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

OF